NV-387 Shows Promising Results in Treating Lethal RSV Infection in Animal Study

NanoViricides, Inc. (NYSE American: NNVC) announced strong results for its broad-spectrum antiviral NV-387 against Respiratory Syncytial Virus (RSV). The study showed normal lung histology in lethally infected animals treated orally with NV-387, indicating potential for a cure. The NV-387 treated group demonstrated complete survival, while the ribavirin-treated group faced progressive lung damage and high mortality.

The study included extended dosing of NV-387 compared with high doses of ribavirin, where the NV-387 group showed no lung damage throughout the study. The ribavirin group exhibited severe lung pathology and reduced survival.

Currently, there is no approved effective treatment for RSV aside from ribavirin, which is highly toxic. According to CDC data, RSV leads to significant hospitalizations and deaths among children under five and adults over 65 annually. NV-387's results suggest it could be a safer, more effective treatment option. NanoViricides plans to advance NV-387 into clinical trials for RSV treatment soon.